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Abstract
Background: The timely and appropriate adoption of new radiation therapy (RT) technologies is a challenge both
in terms of providing of optimal patient care and managing health care resources. Relatively little is known
regarding the rate at which new RT technologies are adopted in different jurisdictions, and the barriers to
implementation of these technologies.
Methods: Surveys were sent to all radiation oncology department heads in Canada regarding the availability of RT
equipment from 2006 to 2010. Data were collected concerning the availability and use of Intensity Modulated
Radiation Therapy (IMRT) and stereotactic radiosurgery (SRS), and the obstacles to implementation of these
technologies.
Results: IMRT was available in 37% of responding centers in 2006, increasing to 87% in 2010. In 2010, 72% of
centers reported that IMRT was available for all patients who might benefit, and 37% indicated that they used
IMRT for “virtually all” head and neck patients. SRS availability increased from 26% in 2006 to 42.5% in 2010. Eighty-
two percent of centers reported that patients had access to SRS either directly or by referral. The main barriers for
IMRT implementation included the need to train or hire treatment planning staff, whereas barriers to SRS
implementation mostly included the need to purchase and/or upgrade existing planning software and equipment.
Conclusions: The survey showed a growing adoption of IMRT and SRS in Canada, although the latter was
available in less than half of responding centers. Barriers to implementation differed for IMRT compared to SRS.
Enhancing human resources is an important consideration in the implementation of new RT technologies, due to
the multidisciplinary nature of the planning and treatment process.
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Background
Major technical advances have occurred in radiation
therapy (RT) over the last two decades. Improvements
in RT planning software and the development of
dynamic multileaf collimators facilitated the develop-
ment of Intensity Modulated Radiotherapy (IMRT) [1].
The potential for superior target conformality and
reduced dose to normal tissues with IMRT can permit
dose escalation which may in turn result in better
tumor control without increasing toxicity [2,3]. These
dosimetric advantages can produce lower toxicity and
possibly better quality of life than seen with non-IMRT
treatment [2-9].
Evidence supporting the use of IMRT is mounting
[2-13]. Veldeman conducted a systematic review of the
clinical evidence for IMRT in 2008 which included 56
comparative studies, 3 of which were randomized con-
t r o l l e dt r i a l s( R C T s )[ 1 1 ] ,a n dc o n c l u d e dt h a tI M R T
reduced treatment-related toxic effects and improved
quality of life. A second systematic review in 2010 [12]
reported reduced acute and late toxicity associated with
IMRT [4-10,12,13]. Three RCTs reported significant
improvement of acute xerostomia with the use of IMRT
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[6,7,9,13], and IMRT for breast cancer was also asso-
ciated with reduced acute and late side effects when
compared to 2D RT in three RCTs [4,5,8]. With further
RCTs in progress [12], additional evidence will soon be
available. Other non-randomized studies have similarly
shown advantages to IMRT for malignancies in other
types of cancer, such as prostate, lung and CNS
[10,12,14].
Similarly, stereotactic radiosurgery (SRS) is another
comparatively recent innovation in which a single high
dose fraction (usually 12 - 24 Gy or higher) is delivered
to a target with extreme precision by means of precise
immobilization and 3-D planning, allowing for minimal
or even no setup margins around the target, thereby
minimizing normal tissue damage. Clinical indications
for SRS include treatment of brain metastases, menin-
giomas, acoustic neuromas, and arteriovenous malfor-
mations [15]. A 2009 systematic review of the role of
SRS in patients with newly diagnosed brain metastases
showed a significant survival advantage for patients with
single brain metastasis who received SRS following
whole brain radiotherapy (WBRT), along with better
local control (and possibly survival) for patients with 2-4
brain metastatic lesions [16]. Guidelines regarding the
use of SRS for brain metastases have been published in
North America [17,18].
Since these technologies were introduced more than a
decade ago, there has been a substantial impetus to
implement them in clinical practice throughout North
America and Europe [19-23]. To our knowledge, there
have been few studies evaluating the availability of these
technologies in developed countries [19-24]. The pur-
pose of this article is to report the results of a series of
surveys across Canada to determine the proportion of
cancer centers that provided IMRT and SRS, how these
technologies were being used, and the obstacles that
hindered their implementation.
Methods
This survey was part of a study concerning workload
and equipment in Canadian radiation oncology centers
sponsored by Canadian Association of Radiation Oncol-
ogy (CARO). From 2006 to 2010, invitations to com-
plete four surveys were sent to Radiation Oncology
department heads of all cancer centers across Canada.
For each survey, reminders were sent electronically on
two separate occasions prior to survey closure. The sur-
vey was initially conducted in 2006 then repeated in
2008, 2009, and 2010. The survey was not conducted in
2007 because of concerns about losing respondent buy-
in, and so that more detailed questions about the use
IMRT and SRS could be integrated into the question-
n a i r e .T h es u r v e yi n c l u d e d 38 cancer centers in 2006
and 2008. One new center was added in 2009 and
another in 2010, bringing the total number of surveyed
centers to 40 (Table 1). The most recent survey closed
in September 2010.
For the purposes of the survey, IMRT was defined
based on the US Medicare definition: created by inverse
planning, and one of the following: a) static segmented
beams with an average of 5 segments per field, or b)
MLC with individually designed compensators (sliding
window or intensity modulated arc therapy). When
available, Tomotherapy™ was categorized with IMRT.
SRS was defined as convergent-beam irradiation that
delivers a high dose of radiation to a small target
volume within the cranium, delivers the total dose in a
single fraction with rapid dose fall-off at the target
boundary, and uses either a frame-based or frameless
system for target localization.
Included in the survey were questions concerning the
availability of computed tomography (CT) simulators,
numbers of linear accelerator units (LINAC), capacity to
deliver IMRT and SRS, and the utilization of IMRT for
specific indications (head and neck, prostate, and breast
cancers). Data concerning the provision of SRS, or the
existence of a referral system in case of SRS unavailabil-
ity, were also collected. If a center did not respond to a
survey one year however had responded in previous
years, we assumed that the equipment had not been
reduced, and equipment information from the previous
year was used. In some cases, direct communication (tel-
ephone/email) correspondence with department respon-
dents was used to clarify missing data. Respondents were
asked to indicate if any of nine barriers to implementing
IMRT or SRS applied to their center, such as training,
equipment configuration, and staffing availability. Partici-
pants were also given the option “other”.
Results
The response rates are summarized in table 1. Annual
response rates varied from 84% in 2006 to 97% in 2008.
The absolute number of reported LINAC units increased
Table 1 Response rates across provinces in Canada.
2006 2008 2009 2010
BC 4/4 4/4 5/5 5/5
Prairies 5/5 5/5 4/5 5/5
ON 12/13 13/13 13/13 14/14
QC 5/10 9/10 8/10 6/10
Atlantic 6/6 6/6 4/6 5/6
Total 32/38 (84%) 37/38 (97%) 34/39 (87%) 35/40 (88%)
Abbreviations: BC: British Columbia, Prairies include: Alberta, Saskatchewan,
and Manitoba, ON: Ontario, QC: Quebec, Atlantic include: New Brunswick,
Nova Scotia, Prince Edward Island, and Newfoundland.
In 2006 and 2008, thirty-eight centers were surveyed. A new cancer center in
BC was added in 2009 and another cancer center in ON in 2010.
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Page 2 of 6from 169 in 2006 to 213 in 2010. The number of LINACs
per 10,000 incident cancer patients was similar across pro-
vinces and ranged from 14.1 to 16.8. The proportion of
LINACs used for IMRT increased from 23.8% in 2006 to
63.2% in 2010. In addition, CT simulation unit numbers
have also grown from a total of 40 in 2006 to 57 in 2010.
CT simulation units per 10,000 incident cancer patients in
2010 ranged from 2.6 to 4.5 across provinces.
IMRT Availability
There has been a significant rise in the proportion of
centers able to provide IMRT from 2006 to 2010 across
all provinces (Figure 1). On a national level, only 37% of
centers provided IMRT in 2006, however this percen-
tage increased to 87.5% in 2010. In 2008, 47% of centers
indicated that IMRT was available for all patients with a
clinical indication, compared to 73% centers in 2010.
Corresponding to the increase in the overall availability
of IMRT, disease site-specific utilization of IMRT also
increased. For example, 65% of cancer centers used
IMRT for head and neck cancer patients in 2008, com-
pared to 80% in 2010, and the proportion of centers
reporting that IMRT was used for “virtually all” head and
neck cases rose from 21% in 2008 to 37% in 2010 (Figure
2A). Similarly, IMRT utilization for “virtually all” patients
with prostate cancer increased from 8% in 2008 to 28%
in 2010, and breast cancer increased from 8% in 2008 to
14% in 2010 (Figures 2B and 2C). There were corre-
sponding reductions in the proportion of centers indicat-
ing that IMRT was not used for these tumor sites.
Barriers to implementing IMRT
T a b l e2s h o w st h er e s u l t so ft h es u r v e y sc o n c e r n i n g
IMRT barriers. Among those centers that indicated a
barrier to the implementation of IMRT, the most com-
monly cited barriers were related to recruitment or
training of skilled personnel. In the 2010 survey, the
most common barriers to IMRT implementation were
the need to train existing planners to plan IMRT (50%)
and the need to hire more planners (30%). Only a min-
ority of centers indicated that limitations in CT simula-
tor (10%) or linear accelerator configurations (10%)
impaired IMRT implementation; however 40% indicated
other barriers to implementing IMRT.
There is a noticeable trend of personnel training-
related barriers becoming less prominent over the years.
For example, the need to train existing physicists to plan
IMRT decreased from 45.5% in 2006 to 20% in 2010.
This is also evident for training existing oncologists and
planners in addition to hiring more personnel who are
trained to perform IMRT planning and treatment.
0
20
40
60
80
100
120
British
Columbia
Prairies Ontario Quebec Atlantic National
Province
P
e
r
c
e
n
t
a
g
e
 
o
f
 
C
e
n
t
r
e
s
 
(
%
)
2006 2008 2009 2010
Figure 1 IMRT availability across Canada. Within the province of
BC, there was a transient drop in 2009 as compared to 2008 as a
result of a single center temporarily suspending IMRT during an
upgrade of their planning software.
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Figure 2 Site-specific IMRT utilization. (A) shows IMRT utilization
for head and neck cancer patients across cancer centers in Canada.
IMRT was provided to “virtually all” patients versus “not used”. (B)
shows IMRT utilization for prostate cancer patients, and (C) shows
IMRT utilization for breast cancer patients.
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Overall, SRS became more widely available from 2006 to
2010 although its growth did not equal that of IMRT
(Figure 3). SRS was available in 26% of centers in 2006,
compared to 42.5% in 2010. Most of the centers (82.6%)
that did not perform SRS themselves reported that they
had established a referral system for patients who were
candidates for SRS treatment. In 2010, 82.5% of centers,
including 20 centers that did not have on-site SRS, indi-
cated that patients who might benefit from SRS had
access to it either directly or by referral.
Barriers to implementing SRS
Among those centers that indicated a barrier to the
implementation of SRS, implementation was hindered
primarily by need to upgrade LINACs or Gamma Knife
equipment (83%) as shown in Table 3. Other obstacles
included the need to train planners to plan SRS and the
need to train more oncologists (50%). Less common
barriers included the need to hire more planners and
physicists. Barriers mentioned under “other” included
lack of a neurosurgery staff and obstacles relating to
patient travel to centers where SRS is available. Unlike
IMRT implementation barriers, SRS barriers tended to
be stable or increased.
Discussion
The adoption and implementation of new radiation
therapy technologies has been a challenge for jurisdic-
tions where public health care systems must also con-
tain costs and manage wait times [25]. There are very
few data regarding the availability and use of these tech-
nologies in different countries. Our data show a rapid
implementation of IMRT across Canada from 2006 to
2010. This holds true for the specific cancer disease
sites targeted in our survey, with increased utilization of
IMRT for head and neck, prostate, and to a lesser
extent, breast cancers.
Implementation of IMRT is not without challenges
however; particularly early in its implementation, IMRT
can require more human resources and is more time
c o n s u m i n gt op l a nt h a n2 Do r3 Dc o n f o r m a lr a d i o t h e r -
apy [26,27]. IMRT also requires a number of supplemen-
tary steps for machine commissioning, plan generation
and quality assurance (QA). There is a large body of evi-
dence providing detailed descriptions of the QA pro-
cesses suggested by a number of organizations including
American Society of Therapeutic Radiation Oncology
(ASTRO) and American College of Radiology (ACR)
[28], American Association of Physicists in Medicine
(AAPM) [27], European Society of Therapeutic Radiation
Table 2 Barriers to IMRT implementation
Barrier to IMRT 2006
(%)
2008
(%)
2009
(%)
2010
(%)
Need to hire more planners 27.3 50 46.7 30
Need to train existing planners to plan IMRT 40.9 72.2 60 50
Need to hire more physicists 40.9 22.2 6.7 10
Need to train existing physicists to plan IMRT 45.5 50 26.7 20
Need to hire more staff to conduct needed
QA checks
27.3 N/A N/A N/A
Need to hire more oncologists 13.6 16.7 13.3 0
Need to train existing oncologists to deliver
IMRT
40.9 44.4 26.7 20
Need to purchase and/or upgrade planning
systems
40.9 22.2 20 0
Need to purchase and/or upgrade linear
accelerators
27.3 44.4 40 10
Need to purchase and/or upgrade CT
simulator
0 22.2 6.67 10
Other 22.7 27.8 40 40
N/A: Data on this barrier was not collected in 2008-2010 surveys
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Figure 3 SRS availability across Canada. There were decreases in
BC and ON as a result of newly established cancer centers that has
not implemented the technology.
Table 3 Barriers to SRS implementation
Barrier to SRS 2006
(%)
2008
(%)
2009
(%)
2010
(%)
Need to hire more planners 20 16.7 38 17
Need to train existing planners to plan SRS 20 33.3 38 50
Need to hire more physicists 30 16.7 12.5 33
Need to train existing physicists to plan SRS 20 33.3 12.5 17
Need to hire more staff to conduct needed
QA checks
20 N/A N/A N/A
Need to hire more oncologists 20 8.3 12.5 17
Need to train existing oncologists to deliver
SRS
20 41.7 37.5 50
Need to purchase and/or upgrade planning
systems
20 66.7 12.5 33
Need to purchase and/or upgrade LINAC or
GK
50 66.7 50 83
Need to purchase and/or upgrade CT
simulator
30 16.7 0 0
Other 30 8.3 12.5 17
N/A: Data on this barrier was not collected in 2008-2010 surveys
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Page 4 of 6Oncology (ESTRO) [29], and Cancer Care Ontario
(CCO) [30]. The resulting standards regarding the imple-
mentation of IMRT programs - practice setting require-
ments; tools, devices and equipment requirements;
professional training requirements; role of personnel; and
requirements for quality assurance and safety - all require
sufficient staff. If these elements are not available, (and
our results suggest that they may be lacking in some
Canadian cancer centers), full implementation of IMRT
may be limited. The difficulties surrounding IMRT
implementation in some centers or jurisdictions may be
related to an inadequate understanding of the need to
provide funding for additional staffing and training pro-
grams in addition to purchasing equipment, and the
diversion of existing human resources towards maintain-
ing high patient volumes [27,31].
In 2010, expert panels convened by Cancer Care
Ontario provided guideline recommendations with
respect to the clinical use of IMRT for a number of can-
cer sites [32], stating that there was adequate evidence
to support the use of IMRT for treatment of head and
neck [33] and prostate cancers [34]. IMRT was also
recommended for cancers of the breast, lung, central
nervous system, and gastrointestinal system in some cir-
cumstances [32,35]. Ideally, these guidelines will facili-
tate appropriate uptake and utilization of IMRT in
Canada’s largest province, and possibly elsewhere.
Availability of SRS is still limited in Canada with fewer
than half of centers providing the treatment in 2010. It
is possible that its availability has not grown as rapidly
as IMRT owing to the more limited indications for its
use, the smaller number of patients who would benefit,
and the relatively greater technical requirements. This
also may explain why personnel trained to perform SRS
are less abundant than those trained to perform IMRT.
Moreover, the capital equipment purchase required to
develop an SRS program appeared to be a more signifi-
cant barrier than was described for IMRT. Interestingly,
most centers that did not offer SRS indicated that they
had an established referral system for eligible patients,
although it is not clear how effectively such referral sys-
tems work for patients in these centers.
Our data is the first published report of the availability
of IMRT and SRS technology in Canada and sheds some
light on the factors that hinder its full implementation.
Corresponding surveys conducted in the UK reported an
increase in the number of centers providing IMRT from
45.8% in 2007 [19] to 76% in 2010 [20]. Obstacles to full
implementation included a shortage of planning staff, in
addition to a lack of specific funding as IMRT was car-
ried out for the same remuneration as conventional treat-
ment. IMRT appears to have been more rapidly taken up
in the United States, with one study finding that 73.2% of
radiation oncologists reported using IMRT in 2004 [21]
as compared to 32% in 2002 [22]. Reasons to adopt
IMRT reported in that survey included the ability to
spare normal tissue and dose escalation, in addition to
economic competition. Similarly, data from Japan show
increased utilization of IMRT in most recent report by
Japanese Society of Therapeutic Radiology and Oncology
(JASTRO) [24]. These studies can facilitate a more
rational approach to health care planning moving for-
ward: new RT technologies will be continually emerging,
and these studies demonstrate the multiple factors other
than clinical need that contribute to patients access to
these technologies.
Conclusions
There are accumulating data documenting the benefits
of IMRT and SRS for reducing the treatment toxicity
and improving disease control in selected patients.
While IMRT and SRS availability is increasing in
Canada, improvement is still required to ensure that
everyone who can benefit from these technologies
potentially has access to them. Due to the multidisci-
plinary nature of RT planning and delivery, investment
in human resources is an important requirement for
adoption and implementation of new RT technologies.
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